Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 12/20 | 0.62 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCND2 | P30279 | 1/20 | 0.51 |
| ▸ | CCND3 | P30281 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.50 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517467 | 0.80 | PTK2 (0.81) | PTK2DCLK1LRRK2TNK2PLK1 | |
| SCHEMBL22658662 | 0.80 | PTK2 (0.81) | PTK2DCLK1LRRK2TNK2PLK1 | |
| SCHEMBL16065698 | 0.79 | LRRK2 (0.63) | DCLK1LRRK2TNK2MAPK7MAP4K1 | |
| SCHEMBL10098748 | 0.79 | LRRK2 (0.79) | DCLK1LRRK2TNK2MAPK7 | |
| SCHEMBL10098757 | 0.77 | TNK2 (0.71) | DCLK1LRRK2TNK2CDK4CCND1 | |
| SCHEMBL20628296 | 0.77 | STK3 (0.71) | PTK2DCLK1LRRK2TNK2CDK4 | |
| SCHEMBL28676729 | 0.77 | PTK2 (1.00) | PTK2PLK1 | |
| SCHEMBL22658579 | 0.75 | PTK2 (0.41) | PTK2 | |
| SCHEMBL29517349 | 0.75 | PTK2 (0.41) | PTK2 | |
| SCHEMBL16065699 | 0.73 | LRRK2 (0.57) | DCLK1LRRK2TNK2MAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3965803-B1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA FARBER CANCER INST INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| CN-113811324-B | Small molecule local Focal Adhesion Kinase (FAK) inhibitors | 达纳-法伯癌症研究公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20220242882-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3965803-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020231726-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | PTK2, CTTN, TNK2 | PTK2 1/4885DCLK1 721/4885LRRK2 908/4885 |
| US-20220242882-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | PTK2, CTTN, TNK2 | PTK2 1/4885DCLK1 721/4885LRRK2 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.